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ABSTRACT: The covalent binding of drugs (metabolites) to
proteins to form drug−protein adducts can have an adverse eﬀect on
the body. These adducts are thought to be responsible for
idiosyncratic drug reactions including severe drug hypersensitivity
reactions. Major advances in proteomics technology have allowed
for the identiﬁcation and quantiﬁcation of target proteins for certain
drugs. Human serum albumin (HSA) and Hb have been identiﬁed
as accessible targets and potential biomarkers for drug−protein
adducts formation, for numerous drugs (metabolites) including β-
lactam antibiotics, reactive drug metabolites such as quinone imines
(acetaminophen) and acyl glucuronides (diclofenac), and covalent
inhibitors (neratinib). For example, MS/MS analysis of plasma
samples from patients taking ﬂucloxacillin revealed that ﬂucloxacillin and its 5-hydroxymethyl metabolite formed covalent
adducts with lysine residues on albumin via opening of the β-lactam ring. Other proteins such as P450 and keratin are also
potential targets for covalent binding. However, for most drugs, the properties of these target proteins including their location,
their quantity, the timing of conjugate generation, and their biological function are not well understood. In this review, currently
available proteomic technologies including MS/MS analysis to identify antigens, precise location of modiﬁcations, and the
immunological consequence of hapten−protein complex are illustrated. Moving forward, identiﬁcation of the nature of the
antigenic determinants that trigger immune responses to drug−protein adducts will increase our ability to predict idiosyncratic
toxicity for a given compound.
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1. INTRODUCTION
A drug−protein adduct is a distinct molecular species resulting
from the reaction of a protein and a chemically reactive drug
(metabolite). The covalent modiﬁcation of proteins can play an
essential role in the pharmacological activity of a wide range of
drugs.1−3 However, covalent modiﬁcation of proteins can also
lead to drug toxicity through several mechanisms including the
induction of an unwanted immune response and drug hyper-
sensitivity. Determining the target proteins of these drug
molecules or reactive metabolites along with the function of
these adducts has been diﬃcult to discern.
The discovery that small chemical compounds could initiate
toxicity by becoming covalently bound to proteins arose
indirectly from studies of the metabolism of carcinogenic
aminoazo dyes in rats.4 Subsequent studies demonstrated that
drug−protein adducts could play a role in drug hypersensitivity
reactions with the extensive research conducted on penicillins
and dinitrophenyl compounds.5,6 Recent advances in mass
spectrometry (MS) have signiﬁcantly aided our understanding of
drug−protein adduct formation.7 This review will describe
advances in MS technology, deﬁne the chemistry of adduct
formation, and highlight the challenges in identifying the
functional role of these adducts in adverse drug reactions
(ADRs).
2. MASS SPECTROMETRIC CHARACTERIZATION AND
QUANTIFICATION OF DRUG−PROTEIN ADDUCTS
Diﬀerent drugs have the ability to bind proteins in diﬀerent ways.
Identifying the precise chemical nature of drug−protein adducts
is an important ﬁrst step in understanding mechanisms of drug
hypersensitivity. Novel mass spectrometric methods have been
developed for the identiﬁcation and quantiﬁcation of drug−
protein adducts, even when formed at very low concentration.
This section gives an overview of these techniques followed by a
more detailed chemical outline of the types of adducts which
have been found.
2.1. Detection of Drug−Protein Adducts. Multiple
methods are used to detect drug−protein adducts (Figure 1).
The most suitable method is dependent on type of sample, the
required speciﬁcity and sensitivity, and the depth of analysis
needed. While MS techniques now dominate drug−protein
Figure 1.An overview of (1) themethods utilized in the isolation and detection of drug−protein adducts and (2) 3-dimentional sample preparation (A−
E) for the enhancement of acquisition sensitivity.
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adduct analysis, traditional methods of protein puriﬁcation are
still essential.
2.1.1. Sample Isolation. Biological samples such as blood
serum contain an extremely complex mixture of proteins,
estimated to consist of more than 10,000 proteins spanning 9
orders of magnitude in concentration.8 Therefore, the
identiﬁcation of target proteins conjugated by drugs is a
challenge. Highly abundant proteins, including HSA, account
for 80% of the total protein concentration in serum.9 HSA is
often targeted by many drugs (metabolites) both due to its high
abundance and its ability to nonspeciﬁcally and reversibly bind to
many lipophilic organic compounds.10,11 Additionally, HSA is
particularly susceptible to modiﬁcation by β-lactam antibiotics,
which bind covalently to available lysine residues.12−16 Isolating
individual protein adducts for mass spectrometric analysis can be
achieved using both HPLC methods (protein depletion and
sample fractionation) and SDS−PAGE. During protein
depletion, a HPLC column containing an aﬃnity antibody/
ligand modiﬁed resin can be used to isolate target proteins from
biological samples.17,18 Alternatively, HPLC fractionation by
protein hydrophobicity can be utilized in the analysis of complex
samples (Figure 1).
The in vitro incubation of drugs (metabolites) with model
proteins such as HSA and glutathione S-transferase pi (GSTP)
has given insight into the chemical mechanisms of drug−protein
adducts formation. For example, the chemical nature, the level of
modiﬁcation, and the stability of adducts can be investigated by
altering incubation conditions such as buﬀer pH, drug
concentrations, and incubation times. By altering these
conditions, it is possible to generate suﬃcient quantities of
drug−protein adducts to determine the structures of potential
adducts and possible chemical pathways for the adducts which
might be formed in vivo. Such in vitro studies are required for the
development of methods with suﬃcient sensitivity for analysis of
drug−protein adducts formed in low abundance from biological
samples.13,18,19 Following the incubation of drug with protein, it
is essential that unbound drug is removed from the sample. The
protein is then analyzed using SDS−PAGE andWestern blotting
using drug speciﬁc antibodies.
2.1.2. Radiometric Detection. The use of radiolabeled
chemicals is essential for understanding drug disposition during
Figure 2. Haptenic structures of the β-lactam−protein complex. Nucleophilic addition to β-lactam ring by lysine residues on proteins results in ring
opening and formation of a stable amide adduct (A); 3D models show that the thiazolidine ring of piperacillin−lysine is exposed for antibody
recognition, whereas it is masked by side chains in ﬂucloxacillin−lysine conjugates (B).
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drug development.20,21 Most pharmaceutical companies synthe-
size isotopically labeled compounds for covalent binding studies
at the lead optimization stage of drug discovery. After both in
vitro or in vivo studies, radioactive drugs covalently bound to
proteins can be detected using accelerated mass spectrometry
(AMS) or liquid scintillation counting (LSC).22 While LSC is
perhaps the least complex and cheapest method, limits of
detection and light frequency disruptions may hamper
identiﬁcation of radioactive material at low concentrations.
Although AMS does enable more precise analysis from smaller
sample volumes, instrumental platforms are very expensive.23
Therefore, radiometric analysis in combination with SDS−
PAGE is the most widely usedmethod for the detection of drug−
protein adducts in complex systems.24−26 Although there are
clear advantages to using radiometric detection, the cost and
storage/disposal of radioactive material make its use in most
research facilities limited.
2.1.3. Drug−Protein Adducts Detection Using Antibodies.
Antibodies speciﬁc to particular molecular targets can be used to
detect drug−protein adducts through a variety of techniques,
including immunoblots and ELISAs. While these are very coarse
methods of hapten detection, they represent a simple way to
quickly detect molecules of interest. In addition, methods used to
separate complex mixtures, through 1-D and 2-D SDS−PAGE
and HPLC, can be used in conjunction with antibodies to
identify drug−protein adducts. Immunoblots are highly
qualitative and are best used to visually display a set of data.
On the contrary, absorbance readings from ELISA samples
provide quantitative measurement which can be statistically
analyzed allowing conﬁdence values to be calculated.
Drug speciﬁc antibodies are used for the detection of drug
modiﬁed proteins. While this practice is widely accepted in the
ﬁeld, there are limitations. As immunoblotting and ELISAs rely
on antibodies that recognize a speciﬁc epitope, cross-reactivity
can be problematic. Figure 2A demonstrates how chemical
moieties are conserved within drug families, such as the
thiazolidine ring in β-lactam antibiotics.19,27 Although the
thiazolidine ring is conserved across the family of β-lactam
antibiotics, penicillin antibodies are not cross-reactive with all
members. Commercially available antibodies raised to benzylpe-
nicillin that recognizes the thiazolidine ring do not cross-react
with other β-lactams such as ﬂucloxacillin, oxacillin, cloxacillin,
Figure 3. Top-down (A) vs bottom-up (B) MSmethod for the characterization of drug−protein adducts. In top downMS, the whole protein is directly
analyzed by MS without digestion, and further fragmentation will enable one to locate the modiﬁcation sites (A);31 in bottom-up MS, proteins are
digested by an enzyme into peptides that can be analyzed by variousMS techniques:MS/MS analysis allows for identiﬁcation of unknown adducts; more
targeted analyses (precursor ion-MS/MS and multiple reaction monitoring-MS/MS) enable one to detect known adducts with great sensitivity (B).
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and dicloxacillin. Although these all possess a thiazolidine ring,
the thiazolidine rings in thesemolecules have beenmasked by the
isoxazole group present in these β-lactams due to the steric
hindrance, thus preventing antibody recognition (unpublished
data, Waddington et al. 2016) (Figure 2B).
2.2. Mass Spectrometry Based Proteomics for Qual-
itative and Quantitative Analysis of Drug−Protein
Adducts. While all of the aforementioned techniques have the
ability to detect drug−protein adducts, more sophisticated tools
are required to characterize the precise chemical nature and for
the identiﬁcation of novel drug−protein adducts. MS is an
exceptionally powerful tool used to elucidate structures of both
known and unknown adducts.28 Through peptide sequencing
withMS techniques, it is possible to determine the precise amino
acid modiﬁcation in the protein structure. In the analysis of
peptides using MS following ionization, mass-to-charge ratios
(m/z) of peptides are calculated. Tandem MS utilizes a second
step to enable further fragmentation and analysis of the resulting
product ions and is the tool of choice when sequencing
peptides.29 MS platforms have also been developed to perform
diﬀerently based on sample type and expected results. A “trade-
oﬀ” between sensitivity and mass accuracy can be observed
between diﬀerent MS platforms,28 where depending on the
sample mixture one may be favored more than the other. This
section will outline the main platforms of MS analysis used for
the detection and quantiﬁcation of drug−protein adducts and
their limitations in particular sample types.
2.2.1. Top-down Mass Spectrometric Analysis. As protein
targets for many drugs (metabolites) in complex biological
samples (e.g., blood plasma) remain unknown, less targeted MS
approaches are required for adducts discovery. Top-down MS
works by introducing whole proteins into the mass spectrometer
where the molecular weight of an intact protein is ﬁrst identiﬁed
(the “top” part, Figure 3A).30 Further fragmentation by tandem
MS (the “down” part) allows identiﬁcation of proteins with full
sequence coverage. Since top-down MS analyses intact proteins
without proteolytic digestion, this strategy is extremely useful for
mapping of labile drug−protein adducts that may be lost during
digestion or cleaved oﬀ in MS analysis.31
Top-down MS is generally performed in high resolution
instruments because of the need to resolve the high molecular
weight of intact proteins.31 Historically, Fourier transform ion
cyclotron resonance mass spectrometers have been mostly used
for top-downMS analysis. More recently, new instruments with a
high resolving power that facilitate tandemMS experiments have
been developed.32 For example, QTOF (quadrupole time-of-
Figure 4.MRM-MS/MSmethods for the detection of drug-modiﬁed proteins. In patients, piperacillin forms four types of haptenic structures with lysine
residues on albumin; each generates a characteristic fragmentation ion ofm/z 160 amu that was used in MRM-MS/MS for the detection of piperacillin-
modiﬁed albumin (A); MS/MS spectrum of the piperacillin-modiﬁed tryptic peptide 539ATK*EQLK545 with piperacillin attached to Lys541(B).61
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ﬂight) MS/MS platforms can simultaneously oﬀer both speed
and accuracy, allowing for large amounts of data to be obtained
from complex samples.33 In proteomics, thousands of highly
accurate spectra can be produced relatively quickly. Con-
sequently, data can be matched to protein databases in order
to identify proteins present in the sample. Certain sample
mixtures are too fragile and will therefore fragment during initial
ionization,34,35 leading to reduced spectra acquisition on typical
quadrupole mass spectrometers. Matrix-assisted laser desorp-
tion/ionization time-of-ﬂight (MALDI-TOF) MS is used with
these samples.34,35 This “soft” ionization technique causes little
or no sample fragmentation, leading to increased resolution of
analyte ions.34,35
Top-down MS is used for the detection of drug modiﬁed
adducts from complex sample mixtures (Figure 3A). Initially, the
protein of interest will be isolated from the sample. This can be
achieved using HPLC, either through protein depletion or
fractionation. While protein depletion using aﬃnity capture is
generally more preferred, this is limited by the availability of
antibodies/ligands to proteins of interest. On analysis, drug−
protein adducts will gain a mass addition, depending on the level
of modiﬁcation, resulting in a mass-shift that would be
identiﬁable on the mass spectra produced (Figure 3A). The
incorporation of novel MS fragmentation techniques such as
electron capture dissociation, has also allowed for the
identiﬁcation of modiﬁcation sites.32,36 Although top-down MS
has proven to be a powerful technique for the identiﬁcation of the
sites of protein modiﬁcation and determination of the order of
multiple modiﬁcation, several technical challenges such as
protein solubility and sensitivity are yet to be resolved.31 An
alternative bottom-up MS approach, involving proteolytic
digestion of proteins into small peptides prior to MS analysis,
has been widely used for identiﬁcation and quantiﬁcation of
drug−protein adducts.
2.2.2. Bottom-up Mass Spectrometric Analysis. The
introduction of peptides into a mass spectrometer is known as
a “bottom-up” approach. In this method, samples undergo
reduction and alkylation, using dithiothreitol and iodoacetamide,
respectively, to unfold the tertiary protein structure and prevent
refolding. Samples are subsequently digested using proteolytic
enzymes (Figure 3B).37,38 Similar to top-down analysis, proteins
must ﬁrst be extracted from the sample mixture using the same
methods. Alternatively, in bottom-up analysis proteins of interest
can be isolated by SDS−PAGE followed by in-gel digestion of the
bands of interest. It is advantageous for samples to undergo
desalting, concentration, and puriﬁcation with a suitable C18
ﬁlter column in order to enhance the sensitivity of detection.39,40
Samples are then loaded into the mass spectrometer as a solution
of digested peptides.
In the discovery stage, QTOF MS/MS is still a powerful
platform used for the detection and analysis of unknown drug−
protein adducts. Product ion scanning is a nontargeted approach
where the initial ion (precursor ion) is detected in the ﬁrst
ionization stage and then further fragmented to detect the full
peptide sequence. Although this is a nonspeciﬁc scanning
technique, modern QTOF platforms can achieve up to 25 MS/
MS spectra per cycle, providing masses of sample data for
analysis. Similarly, precursor ion scanning can be used to identify
suspected modiﬁcations in an unknown sample (Figure 3B). In
precursor ion scan mode, particular precursor ions that produce a
preselected product ion will be detected, generating a record of
analytes that give clues to potential drug modiﬁcations. For
example, a characteristic peak at m/z 160, corresponding to the
cleavage of the thiazolidine ring, can be used for identifying
adducts formed by β-lactam antibiotics (Figure 4A).16,18 This
type of experiment is extremely useful for monitoring unknown
protein targets for known adducts within a complex mixture.
While this is a partially targeted approach to drug−protein
adducts detection, it can give rise to false positives. Ions that are
not derived as a result of drug cleavage may correspond to the
same mass; therefore, it is important to manually characterize the
amino acid sequence on any spectra where drug modiﬁcation is
suspected. Putative drug modiﬁed peptide sequences can be
matched against peptide databases with the hope of identifying
protein origins. Although in theory this is a promising method to
identify novel drug−protein adducts, in practice it is laborious
and takes a trained eye to calculate peptide sequences.
Multiple reaction monitoring (MRM) is a more targeted MS
tool enabling the user to scan for speciﬁc parent and fragment
ions. MRM transitions speciﬁc for drug modiﬁed peptides are
generally designed for this purpose. The parent ions can be
calculated for all possible peptides derived from theoretical
digests with a mass addition of proposed haptens. In some cases,
peptides with missed cleavage sites are commonly used when
drugs (metabolites) are covalently bound to lysine or arginine.
The parent ion masses are then paired with the proposed
fragment masses derived from drug molecules. MRM-MS/MS
actively searches for predeﬁned m/z ratios during data
acquisition, and further fragmentation is only performed on
the ions that match the search criteria.41 Instead of obtaining full
MS/MS analysis, only a small number of speciﬁc fragment ions
are analyzed, making analysis more speciﬁc and sensitive. By
monitoring of the speciﬁc ions of interest, MRM-MS/MS
scanning has the capability to detect extremely low levels of drug-
modiﬁed proteins present in the complex biological matrices
(Figure 3B).42
MRM is particularly useful in the identiﬁcation of proteins
modiﬁed by β-lactam antibiotics. Protein digestion using known
enzymes, such as trypsin, enables theoretical digests and
expected m/z ratios of peptides to be calculated. β-Lactam
antibiotics covalently bind to exposed NH2 groups on the side
chains of lysine residues.43 When a drug is covalently bound,
proteolytic digestion of trypsin cleaving the C-terminal side of
lysine and arginine is interrupted.44 This is due to the chemical
morphology at a β-lactam antibiotic bound lysine residue
blocking chemical interactions, thus incorporating missed
cleavage sites.18,45 Missed lysine cleavages are therefore included
when performing theoretical digests. This enables the speciﬁc
selection of peptides with the potential to be modiﬁed at a
nonterminal lysine residue. To speciﬁcally search for drug
modiﬁed peptides, the m/z ratios are calculated with a mass
addition corresponding to the molecular weight (MW) of
haptens. When analyzing the spectra, characteristic features of
the drug molecule can be identiﬁed, for example, the cleavage of
thiazolidine ring of penicillin leads to the fragment ion at m/z
160.16,18
Sample preparation is important in being able to successfully
identify drug−protein adducts, especially when they are present
in low abundance. Therefore, a three-dimensional approach to
sample preparation is performed. Proteins of interest can be ﬁrst
isolated from complex biological samples using aﬃnity capture
and subjected to proteolytic digestion. After digestion, HPLC
platforms are used for ion exchange, separating samples into
multiple fractions depending on their ionic interactions with the
column used. Each fraction will then be puriﬁed to remove the
salt using C18 reverse phase HPLC, before MS analysis. Sample
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preparation in this way spreads the peptide mixture across two
gradients, enhancing the sensitivity of detection.
2.2.3. Quantiﬁcation. MS plays a major role in both relative
and absolute quantiﬁcation from complex sample mixtures.
There are many potential applications for the use of this
technology, notably for comparison of healthy volunteer vs
diseased patient samples in identiﬁcation of disease bio-
markers.46 It is widely understood that peak intensity alone is
not a true indicator of the quantity of analytes due to the
ionization eﬃciency and the detection of diﬀerent peptides.47
While this can be used to quantify similar peptides across
diﬀerent samples, moderated using standards throughout, more
sensitive techniques have been developed in order to accurately
quantify protein in mixed samples.48
Stable isotope labels using tandem mass tagging (TMT) can
be used for relative quantiﬁcation, although this comes at a
greater cost, and sample preparation is perhaps more time-
consuming.49 Isobaric tag for relative and absolute quantiﬁcation
(iTRAQ) is a method used to quantify multiple proteins in a
single sample, using tags which covalently bind to theN-terminus
and side chains of lysine amino acids.48,50 Individual samples are
digested and tagged with one of eight diﬀerent iTRAQ
reagents.48,51 Each tag has the same molecular structure and
overall mass; however, variable isotopic masses alter the m/z
ratios detected.52 Samples are pooled and analyzed using LC-
MS/MS, where database matching can identify the m/z of the
reporter ion tags, and relative protein quantiﬁcation can be
calculated.53,54 While employing this technique is initially more
time-consuming, the analysis of a single spectrum allows for a
more streamlined approach.
Absolute quantiﬁcation utilizes targeted MRM LC-MS/MS
techniques. Here, labeled synthetic peptides of known
concentrations are mixed within the samples. Synthetic peptides
produce a standard curve which can be used to back calculate the
concentrations of target peptides; unfortunately, synthetic
standards are expensive and not always commercially available.
As with relative quantiﬁcation, iTRAQ is a well-deﬁned reagent
for this method.51 While data acquisition is relatively
straightforward, analysis requires powerful software to interpret
the spectra. Multiple platforms exist consisting of databases
enabling spectra to be matched with known proteins. However,
many open access databases only contain peptide sequences
rather than whole proteins. Commercial packages are available to
enable full protein comparisons to be made, e.g., ProteinPilot;
however, this is expensive software that requires signiﬁcant
information technology infrastructure.50
While the use of TMT gives an accurate measurement of both
relative and absolute protein quantiﬁcation, its use in drug−
protein adducts analysis is limited, especially with β-lactam
antibiotics. β-Lactams covalently bind to the free amino group on
lysine side chains, blocking the binding motif used by TMT,
leading to partial labeling at best. Instead, radiometric methods
are attributed as being the “gold-standard” method for the
quantiﬁcation of drug−protein adducts,55−57 which could
potentially be used to quantify the covalent binding of β-lactam
antibiotics to proteins in vitro. Proteins of interest, e.g., HSA, can
be incubated with radiolabeled penicillins under the required
conditions. Quantiﬁcation of covalent bound drugs can be
achieved using LSC after the unbound drug is washed away. As
long as protein amount and radiation amount are known, the
number of drugmolecules per proteinmolecule can be calculated
accurately.
2.3. Protein Adducts as Biomarkers for Exposure to
Reactive Drug Metabolites. Bioactivation of drugs to reactive
metabolites (RMs) that can covalently bind to macromolecules
remains a major concern for drug development.57 Drugs are
usually metabolized via phase I and II reactions. Metabolism
results in the formation of stable metabolites and loss of
biological activity of the parent drug. This is known as
detoxiﬁcation. However, a large number of drugs have been
shown to form RMs that could, in theory, provoke a toxic
response. Therefore, high-throughput strategies have been put in
place to screen for the formation of RMs in the early stages of
drug discovery.57 RMs, such as quinone imines, epoxides, and
acyl glucuronides (Table 1), are reactive electrophiles, which can
rapidly be inactivated by GSH conjugation or undergo covalent
Table 1. Drug Modiﬁed Proteins Detected in Vitro and in Vivo
targeted proteins
drugs reactive motif in vitro in vivo
modiﬁed
AA adducts formed ref
penicillin beta-lactam albumin albumin Lys amide 13,16,18
diclofenac acyl glucuronide
quinone imine
GSTP, albumin albumin Lys, Cys Schiﬀ base thioether 105,175
abacavir enone GSTP, albumin albumin Lys, Cys,
His
Michael adducts 83,84,176
DNCBa aryl halide K14 albumin NA Lys, Cys,
Tyr
aromatic substitution 177,178
acetaminophen quinone imine GSTP, albumin, CP2C6_RAT, MADD_RAT,
MGST1_RAT, NU5M_RAT
albumin Cys thioether 74,77,179
nevirapine arene oxide quinone
methide, sulfate
GSTP, albumin, Hb Hb, albumin Cys, His,
Val
thioether Michael
adducts
69,70,72,82
carbamazepine arene oxide epoxide GSTP, albumin albumin Cys, His thioether 65
isoniazid hydrazine albumin albumin Lys amide 180
MRL-Aa α,β-unsaturated imine liver and kidney proteins acyl-CoA
synthase
Lys, Ser,
Cys
Michael adducts 181
ibrutinib α,β-unsaturated amide albumin NA Cys, Lys Michael adducts 182
SMXa Nitroso GSTP, albumin Myeloperoxidase NA Cys sulﬁnamidesulfonamide 96−98
houttuynin β-keto aldehyde Hb, albumin NA Val, Lys Schiﬀ base, pyridinium 183
bergamottin γ-ketoenal Cyp3A4 NA Gln Michael adducts 184
aDNCB: dinitrochlorobenzene. MRL-A: 1-{4-[(4-phenyl-5-triﬂuoromethyl-2-thienyl)methoxy]benzyl}azetidine-3-carboxylic acid. SMX: sulfame-
thoxazole.
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binding to macromolecules. Therefore, drug−GSH conjugates
or their further degradation products, i.e., cysteine or
mercapturate products excreted in the urine, can be used as
biomarkers for exposure to RMs. Furthermore, characterization
of the structures of these thiol conjugates can inform the
molecular mechanisms of drug bioactivation, thus leading to safer
drug design.58,59 However, some RMs that have extremely short
half-lives may bind directly to the enzymes responsible for their
generation, leading to mechanism based enzyme inhibition
(MBI). Another possibility is that the RMs may have great
aﬃnity toward intracellular proteins and react preferentially with
these targets in diﬀerent tissues. The intracellular proteins appear
to be prominent targets for short-lived RMs or RMs that are
likely to accumulate within cells. Furthermore, during chronic
exposure, stable protein adducts are expected to accumulate in
the body due to the long half-lives of proteins, e.g., 120 days for
human Hb60 and 21 days for HSA,32,36 and thus augment the
sensitivity of detection of low level of RMs. Therefore, drug−
protein adducts that reﬂect the systemic exposure to RMs in vivo
may be more relevant when used as an alternative to GSH
adducts for biomarkers. In this section, some common reactive
drug (metabolites) and their reactions with proteins to form
drug−protein adducts are discussed, with an emphasis on MS
characterization of these adducts.
2.3.1. β-Lactam Antibiotics. β-Lactam antibiotics are widely
prescribed for bacterial infections and are a frequent cause of
allergic reactions. β-Lactams are intrinsically reactive and can
form drug−protein adducts with lysine residues on protein
through the nucleophilic opening of the β-lactam ring. Recent
studies investigating blood from patients using advanced MS
methods have identiﬁed albumin as the major target for β-
lactams. The precise haptenic structures and the exact location of
modiﬁcation on albumin have been deﬁned for a number of β-
lactams (Table 2).16,18,61 At low concentrations, diﬀerent β-
lactams appeared to selectively target diﬀerent lysine residues in
HSA, with noncovalent interactions positioning the drugs in
favorable orientations in the protein-binding pocket to facilitate
covalent binding. Thus, the three-dimensional shape of the drug,
as well as its inherent chemical reactivity, determines the
selectivity of covalent binding. However, at high concentrations
and with prolonged incubation, multiple residues were modiﬁed
by diﬀerent β-lactams. Multiple sites of adduction are most likely
observed in vivo with reactive drugs administered at high doses,
e.g., penicillins; for the majority of RMs, more selective
adduction is expected owing to the low levels of RMs. It is
worth noting that multiple sites of adduction identiﬁed via tryptic
digestion do not tell the number of adducts per molecule of
proteins, which may be determined by analysis of whole proteins
(top-down MS).
Flucloxacillin modiﬁes up to 10 lysine residues in HSA in vitro,
with Lys190 and Lys212 being themost reactive. Analysis of HSA
isolated from the serum of eight ﬂucloxacillin-tolerant patients
Table 2. Drug Modiﬁed Albumin (Accession Number P02768) Detected in Patientsa
aBP, benzylpenicillin; PIP, piperacillin; Amox, amoxicillin; FLU, ﬂucloxacillin; ABC, abacavir; NVP, nevirapine; DCF AG, diclofenac acyl
glucuronide; APAP, acetaminophen.
Chemical Research in Toxicology Review
DOI: 10.1021/acs.chemrestox.6b00147
Chem. Res. Toxicol. XXXX, XXX, XXX−XXX
H
also showed that modiﬁcation of Lys190 and Lys212 occurred in
all the patients, with up to nine other modiﬁed lysine residues
being detected. In addition, the detection of HSA adducts
derived from its 5-hydroxymethyl metabolite provides the
evidence of local hepatic exposure to this metabolite.18
Incubation of HSA with piperacillin results in the formation of
two distinct haptens: a cyclized and a hydrolyzed form in which
the dioxopiperazine ring had undergone hydrolysis.61 Piperacillin
was able to modify up to 13 out of 59 lysine residues at high
concentrations, with Lys541 being the only reactive residue at
lower concentration. Four of these (Lys190, Lys195, Lys432, and
Lys541) were also detected in plasma from 4 piperacillin treated,
tolerant patients. In addition to the hydrolyzed and cyclized
haptens of piperacillin, two further adducts derived from the
desethyl metabolite of piperacillin were also detected in patients’
plasma (Figure 4A). A typical MS/MS spectrum representing
HSA peptide 539ATKEQLK545 modiﬁed by piperacillin at Lys541
is shown in Figure 4B. Compared with piperacillin, benzylpeni-
cillin targeted diﬀerent lysine residues at low concentrations:
benzylpenicillin and its rearrangement product, benzylpenicil-
lenic acid, modiﬁed Lys199 and Lys525, respectively, whereas
exposure to higher concentrations resulted in up to 16 further
lysine modiﬁcations. Fourteen diﬀerent modiﬁed lysine residues
were identiﬁed on HSA isolated from patients’ serum (Table
2).16 Apart from albumin adducts, amoxicillin-modiﬁed trans-
ferrin and immunoglobulin were also detected when human
serum was incubated with amoxicillin in vitro. The hapten was
identiﬁed as amoxicilloyl on Lys190, Lys199, and Lys541 with
higher concentrations eliciting more extensive modiﬁcation.62
Unlike the penicillin class of β-lactams, meropenem and
aztreonam contain a β-lactam ring fused to another ring that is
diﬀerent from the thiazolidine rings present in penicillins. Thus,
Meropenem and aztreonam formed complex and structurally
distinct haptenic structures with lysine residues on HSA. Each
drug modiﬁed Lys190, with less commonmodiﬁcations at Lys12,
Lys199, and Lys 351 for meropenem and Lys137, Lys432, and
Lys541 for aztreonam.13
2.3.2. Arene Oxides and Epoxides. Bioactivation of aromatic
compounds normally leads to the formation of arene oxides,
while in the case of alkenes, the corresponding epoxides can be
formed. Both arene oxides and epoxides are reactive and
preferentially react with thiol nucleophiles on proteins.
Carbamazepine is an example that generates an epoxide and a
number of arene oxide reactive intermediates (Figure 5A).
Carbamazepine−protein adducts have been detected in a
number of in vitro systems. Incubation of CYP3A4 supersomes
Figure 5. Epoxidation to generate reactive metabolites. Oxidation of carbamazepine by CYP enzymes leads to the formation of both arene oxides and
epoxide metabolites (A); possible metabolic pathways for the formation of nevirapine reactive metabolites (B).
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with carbamazepine resulted in the formation of carbamaze-
pine−CYP3A4 adducts, which may give rise to the autoanti-
bodies detected in the sera of carbamazepine hypersensitivity
patients.63 Bioactivation of 3-hydroxy-carbamazepine and 4-
hydroxy-phenytoin by myeloperoxidase led to covalent binding
to the tyrosine of a lysozyme when used as a model protein.64
Formation of hapten−protein complexes have also been
detected with reactive metabolites derived from further oxidation
of 2- and 3-hydroxy-carbamazepine, e.g., iminoquinone and O-
quinone. Furthermore, carbamazepine 10,11-epoxide, an abun-
dant and pharmacologically active metabolite believed to be
chemically stable, has been demonstrated to be chemically
reactive and form protein adducts with HSA and GSTP. MS
analysis has identiﬁed the dihydrohydroxy thioether adduct at
Cys47 on GSTP and two histidine adducts (His146 and His338)
on HSA.65
Nevirapine (NVP), a non-nucleoside HIV-1 reverse tran-
scriptase inhibitor, appears to be predominantly metabolized by
CYP3A4 and CYP2B6 to a number of hydroxyl metabolites in
humans. Identiﬁcation of two isomeric NVPmercapturates in the
urine of patients and rats has provided the evidence that NVP
undergoes bioactivation to heteroarene oxides and quinone
methide intermediates in vivo (Figure 5B).66−68 The NVP 3-
mercapturate is likely to be derived from either 2,3-epoxide or
3,4-epoxide, whereas the NVP 12-mercapturate is a putative
product of a quinone methide intermediate. The quinone
methide intermediate can be derived from direct oxidation of
NVP or from NVP-12-sulfate metabolite. It has been
demonstrated that sulfation of 12-hydroxyl NVP followed by
the dissociation of sulfate could also lead to the formation of the
quinone methide. NVP-protein adducts have been detected in
the skin, liver, and plasma in vitro and in vivo in animal
studies69−71 using radiometric and immunochemical methods.
However, neither the haptenic structure of these adducts nor the
targeted amino acids were characterized by these studies.
Therefore, it is impossible to determine which reactive
intermediates are responsible for protein conjugation.
The in vitro incubation of 12-mesyloxy NVP, a chemical
surrogate of 12-OH NVP, with model proteins such as HSA and
Hb, has enabled the identiﬁcation of 14 adducts involving
cysteine, lysine, histidine, serine, tryptophan, and the N-terminal
valine of Hb.69 However, these ﬁnding do not accurately mirror
the true adduct formed in vivo as 12-mesyloxy NVP is more
reactive than 12-sulfoxyl-NVP. Instead, NVP modiﬁcation was
only detected on cysteine and histidine when the 12-sulfate NVP
metabolite was incubated with HSA and GSTP. Three histidine
Figure 6. Michael acceptors as potential electrophiles. Drugs with aniline structural alerts can be oxidized to quinone imine reactive metabolites (A);
possible metabolic pathways to form reactive α,β-unsaturated aldehyde metabolites that covalently bind to cysteine, lysine, and histidine residues on
proteins (B).
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residues (His146, His242, and His338), one cysteine residue in
HSA, and a single cysteine residue in GSTP were identiﬁed.
Nonetheless, NVP adducts formed with N-terminal valine in
Hb69 and His146 in albumin72 were detected in humans taking a
therapeutic dose of NVP, reaﬃrming the relevance of in vitro
studies.
2.3.3. Michael Acceptors. Michael acceptors, including
quinones, quinone imines, quinone methides, and α,β-
unsaturated aldehydes, are the most common types of RMs for
numerous drugs. For example, in many drugs with aniline
structural alerts, including acetaminophen (APAP), lapatinib,
and amodiaquine (Figure 6A), bioactivation can lead to the
formation of quinone imine intermediates; drugs with thiophene
and furan moieties can undergo epoxidation, followed by ring
opening to α,β-unsaturated aldehydes. In addition, Michael
acceptors have been widely used as covalent drugs for cancer
therapy such as the covalent kinase inhibitors ibrutinib and
afatinib. Michael acceptors are normally considered as soft
electrophiles and preferentially react with cysteine and histidine
residues on proteins through 1,4-addition. In the case of α,β-
unsaturated aldehydes, further cross-linking adducts may be
formed after the initial 1,4 addition.
A classic example of the quinone imine formation is APAP,
which is safe and eﬀective at recommended doses, but can cause
liver toxicity in overdose. APAP can be oxidized by P450 to the
reactive N-acetyl-p-benzoquinoneimine (NAPQI), which can be
detoxiﬁed by conjugation with GSH. However, overdose of
APAP may result in covalent binding to proteins thus causing
hepatotoxicity.73 Covalent binding of NAPQI to cysteine
residues in proteins has been detected in a number of in vitro
and in vivo systems.74−77 Using an electrochemical ﬂow-through
cell coupled with LC-MS, Lohmann et al. was able to generate
and detect APAP-modiﬁed Cys121 in β-lactoglobulin A.78 More
importantly, high concentrations of APAP adducts were detected
in both adult and pediatric samples obtained from patients with
acute liver failure (ALF). A recent pharmacokinetic study
demonstrated that the level of APAP protein adducts in adults
with APAP overdose and ALF correlated well with the severity of
toxicity, supporting their use as speciﬁc biomarkers for APAP
toxicity in patients with ALF.76,79 However, the HPLC methods
used in these studies to measure APAP−cysteine conjugates after
proteolysis of all serum proteins do not deﬁne either protein
targets or the position of cysteine residues within the proteins for
modiﬁcation. Therefore, an accurate quantitative relationship
between APAP adducts at speciﬁc cysteine residues and APAP
toxicity cannot be established.
Another important Michael acceptor is an α,β-unsaturated
aldehyde, which can be generated by sequential metabolism of
drugs with thiophene, furan, and β,γ-alcohol moieties. Abacavir
(ABC), a nucleoside-analogue reverse transcriptase inhibitor,
undergoes extensive oxidative metabolism in humans, yielding a
number of isomeric carboxylic acids through a two-step oxidation
process. Oxidation by alcohol dehydrogenase80 followed by bond
migration yields an electrophilic α,β-unsaturated aldehyde
species (Figure 6B). Charneira et al. have shown that the ABC
α,β-unsaturated aldehydes (ABCA) react with the N-terminal
valine residue of Hb in vitro81 and in rats and patients.82,83 Recent
in vitro studies using GSTP and HSA as model proteins by Meng
et al. have demonstrated that ABCA can form novel intra-
molecular cross-linking adducts via Michael addition, followed
by nucleophilic adduction of the aldehyde with a neighboring
protein nucleophile. Adducts were detected on Lys159, Lys190,
His146, and Cys34 residues in subdomain IB of HSA. ABC-
modiﬁed Cys47 and cross-linking adducts derived from Cys47
and Ser46 were identiﬁed in GSTP. More importantly, similar
adducts were also detected in patients with ABC therapy.84
In recent years, many covalent drugs that contain Michael
acceptors have been developed for the treatment of cancer or
hepatitis C infections.2,3 By selective covalent modiﬁcation of a
speciﬁc amino acid residues in the active site of the receptor or
enzyme, this class of drugs provides increased biochemical
potency and greater isoform selectivity, and can also overcome
clinical resistance to mutant forms of the target enzymes.3
Afatinib and neratinib (Figure 7), which both contain an α,β-
Figure 7. Covalent drugs containing weak Michael acceptors. Afatinib, a covalent inhibitor for the treatment of lung cancer, acts by covalent binding to
cysteine residues at the catalytic sites of the receptors (A);85 HSA has been identiﬁed as an oﬀ-target protein for some covalent inhibitors, for example,
neratinib was found to bind to lysine residues on HSA (B).86
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unsaturated acrylamide moiety, can covalently bind to cysteine
residues in a number of tyrosine kinases and exhibit great clinical
eﬃcacy against tumors.85 For example, afatinib is capable of
forming Michael adducts with cysteine residues within the
catalytic sites of EGFR (Cys797), HER2 (Cys805), and HER4
(Cys803) (Figure 7A). Despite promising eﬃcacy across a broad
range of disease, there have been great concerns that covalent
drugs might cause potential oﬀ-target toxicity. However, drugs
designed to bind covalently to speciﬁc pharmacological targets
generally exhibit a low degree of interaction with oﬀ-target
cellular proteins owing to the weakly electrophilic warheads that
are incorporated into them and a much greater aﬃnity for the
target receptors or enzymes. The oﬀ-target reactivity of covalent
drugs has been assessed in a quantitative and qualitative manner
by using 14C-labeled compounds. Neratinib has been shown to
form albumin adducts via Michael addition with lysine attacking
the β-carbon of the amide moiety. MS analysis of neratinib-
modiﬁed albumin conﬁrmed Lys190 of HSA was covalently
bound to neratinib (Figure 7B).86 Further quantitative analysis
has shown that covalent binding of neratinib to HSA is pH, time,
and temperature dependent but not substrate concentration
dependent, especially in the therapeutic range.24 Apart from
albumin, identiﬁcation of other critical proteins potentially
targeted by covalent drugs is necessary for the assessment of the
toxicity associated with them. For example, the enzyme
ferrochelatase that catalyzes the conversion of protoporphyrin
IX into heme has been recently found to be an oﬀ-target of many
kinase inhibitors, providing a possible explanation for the
phototoxicity associated with these drugs in melanoma
patients.87
Despite the unique advantages of drugs which act as “covalent
inhibitors”, there are general concerns regarding immune-
mediated toxicity that could arise from covalent binding with
oﬀ-target proteins. Several approaches, including increase of the
inherent aﬃnity to target enzymes to improve the selectivity and
the use of weak electrophilic functionalities to minimize the
nonspeciﬁc reactivity, have been employed for designing and
optimizing this class of drug. As a new emerging class of therapy,
little is known of their safety proﬁles. Several cutaneous adverse
reactions associated with “covalent inhibitors” have been
reported in clinical trials;88,89 however, the underlying
mechanisms are not clear. Advanced MS-based proteomics that
enable us to identify the oﬀ-target proteins, coupled with in vitro
model systems for the elucidation of possible immunological
events, may provide insights into both the eﬃcacy and safety of
this class of drug.
2.3.4. Aromatic Amines. Compounds containing aromatic
amines are well-known to induce a variety of toxicities including
carcinogenicity and hypersensitivity. The primary bioactivation
pathway of an aromatic amine is the oxidation of the amino group
to form a hydroxylamine, which can form arylnitroso derivatives
by further oxidation or other reactive species by sulfation/
acetylation.90 The arylhydroxylamines and their oxidized
arylnitroso derivatives can react with cysteine residues of GSH
or proteins to form sulfenamide and sulﬁnamide adducts,
respectively. In addition, direct reactions of hydroxylamines
with other amino acid residues, including histidine and
tryptophan, have also been reported.91 Both Hb and HSA have
been targeted by a number of aromatic amines in vitro and in
animals.
Sulfamethoxazole (SMX) is a sulphonamide containing
antimicrobial associated with a high incidence of hypersensitivity
including fever, rash, and hepatitis. The hypersensitivity reactions
are thought to be a consequence of bioactivation to the
hydroxylamine metabolite (SMX-NOH) and its further
oxidation product, nitroso-sulfamethoxazole (SMX-NO).
These reactive metabolites act as haptens and activate T-cells
via the covalent modiﬁcation of MHC bound peptides and non-
MHC associated proteins.92−94 SMX-NO binds extensively to
cysteine residues on serum and cellular proteins, forming
complex and multiple haptenic structures including sulfona-
mides, N-hydroxysulﬁnamides, and N-hydroxysulfonamides
Figure 8. Oxidation of sulfamethoxazole to a nitroso reactive metabolite that forms a number of haptenic adducts with cysteine residues on proteins.
Similar adducts may be also formed by dapsone with cysteine residues on proteins.
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(Figure 8).95−97 Likewise, dapsone is oxidized to a number of
RMs, leading to protein adduct formation. Dapsone−protein
adducts have been detected in dendritic cells as well as
keratinocytes.98,99
2.3.5. Acyl Glucuronides. Many carboxylic acid-containing
drugs such as nonsteroidal anti-inﬂammatory drugs (NSAIDs)
are metabolized to β-1-O-acyl glucuronides (AGs), which are
able to form adducts with nucleophiles on proteins. In theory, the
resulting protein adducts may cause toxicity through the
impairment of physiological functions. AGs can modify proteins
through two distinct pathways. Direct reactions with certain
amino acid residues on proteins, such as lysine, cysteine, and
arginine, lead to transacylation adducts. Alternatively, migration
of the acyl group may yield the 2-, 3-, and 4-acyl isomers, which
are relatively less labile to direct hydrolysis but exhibit great
chemical reactivity of anomeric sugar esters. Reaction with amine
nucleophiles followed by an Amadori rearrangement generates a
more chemically stable 1-amino-2-keto product (Figure 9).100
Structure−reactivity studies have revealed that carboxylic acids
with a higher degree of alkyl substitution at the α-carbon exhibit
increased stability;101 thus, the ibuprofen AGs display a longer
half-life (3.3 h in pH 7.4 buﬀer) than AGs of diclofenac and
ibufenac.100
HSA has been identiﬁed as a major target for many AGs in
plasma because of its abundance and the presence of several
accessible nucleophilic amino acid side chains.102−105 However,
other proteins in the liver, kidney, skeletal muscle, and intestine
have also been reported as targets for AGs.106 For example, the
AG of diclofenac and many other carboxylic acid containing
NSAIDs has been found to selectively bind to several proteins
located on the apical (bile canalicular) domain of the hepatocyte
plasma membrane.107 By use of immunochemical techniques,
hepatic dipeptidyl peptidase IV has been identiﬁed as a common
target for the AGs of a number of drugs including zomepirac,
although other targets are yet to be found.
In addition to AGs, carboxylic acid drugs can undergo
bioactivation to form electrophilic acyl-coenzyme A thioester
derivatives (acyl-CoAs), which have been shown to be up to 40−
70 times more reactive.108 Acyl-CoA derivatives of several
carboxylic acid drugs including zomepirac and tolmetin have
been detected in vitro and in vivo.109,110 In vitro incubation of the
CoA conjugates of a number of NSAIDs with human liver
microsomal proteins conﬁrmed that the reactivity of CoA
derivatives was signiﬁcantly higher compared to those of their
corresponding oxidative metabolites and AGs. Therefore, it is
plausible that CoA conjugates can contribute to the toxicity
observed with carboxylic acid drugs.111−113
Despite extensive study of the chemical reactivity of AGs, their
precise role in toxicity remains undeﬁned. Retrospective analysis
of the toxicity associated with numerous carboxylic acid
containing drugs revealed that the stability of AGs exhibits
some degree of correlation with the risk of toxicity. Therefore,
the half-lives of AGs have been widely used for selection of
compounds in drug development. However, this has been
challenged based upon the poor correlation between the extent
of covalent binding and the risk of toxicity for certain NSAIDS,
Figure 9. Mechanisms of protein adduct formation by reactive acyl glucuronide and thioester metabolites of carboxylic acid containing drugs.
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such as ibuprofen114 and naproxen.115 Therefore, other factors
such as daily dose, oxidative stress, and transporters, along with
chemical reactivity, might be required for the holistic assessment
of AG toxicity risks.
3. FUNCTIONAL ASPECTS
3.1. Understanding the Function of Drug−Protein
Adducts. While the detection and discovery of drug−protein
adducts has been diﬃcult, new MS techniques have made this
process more feasible, leading to the detection and precise
structural deﬁnition of a number of adducts. Understanding the
mechanistic function of these adducts, however, remains a
challenge. Although we have discussed the resurgence of drugs
which bind covalently as part of their pharmacological function,
most drugs in use today bind to receptors within the body in a
noncovalent manner and are usually designed to limit binding to
proteins.2 Unfortunately, the metabolic systems in the liver that
can cause the formation of RMs make drug−protein adduct
formation inevitable. Adduct formation seems to correlate with
the incidence of ADRs, but it has been diﬃcult to make a
mechanistic link between the two. The nature of ADRs is highly
variable; they are unrelated to the normal pharmacological action
of the drug and are often categorized as idiosyncratic ADRs.116
As ADRs only occur in some patients, these reactions can be
attributed to the individual biology of patients suggesting that
highly speciﬁc mechanisms are involved. However, the exact fate
of drug−protein adducts and their roles in ADRs remain unclear.
Many studies have addressed the role of adduct formation in
drug toxicity that can be categorized into two major pathways:
direct toxicity and immune activation. In direct toxicity, either
the adduct itself is toxic to the body or the drug binds to a protein
which has a functional role in the body. In the latter, the drug
binds in such a way that it changes the biological function of that
protein. In the immune activation pathway, an adduct can be
recognized by the body’s immune system as a foreign antigen.
This can cause an adverse immunologically driven event. The
nature of these two pathways will be discussed with reference to
speciﬁc examples, and a prominent feature of this analysis will
show that even within one pathway a vast array of mechanisms
appear to be involved.
3.2. Direct Toxicity. The structure of a protein is highly
speciﬁc; therefore, covalent binding will alter the structure of a
protein and aﬀect its function.55 Incidentally, many drugs act on
liver proteins causing hepatotoxicity.117−119 Although other
organ systems are also aﬀected by adduct formation, the liver
seems to have a functional role in mediating these reactions. The
formation of RMs and their direct impact on the liver including
the generation of reactive oxidative species and covalent binding
to crucial proteins can be harmful, but RMs are not usually
generated in suﬃcient quantities to bind to proteins; they can
bind to thiols such as glutathione and will be excreted as
chemically inert compounds.120 There are a number of such
protective mechanisms in the liver such as the NRF2/KEAP
pathway.121 However, when these protective mechanisms are
depleted, drug metabolites that can bind to functional proteins
within the liver may induce direct toxicity.122 The previous
section outlines examples of some of these target proteins.
Importantly, the focus for this review is the contribution of
drug−protein adducts to toxicity rather than the action of RMs
and their depletion of protective mechanisms. Drugs can bind to
proteins to adversely alter protein function, also known as
mechanism based inhibition. Alternatively, a protein adduct can
itself be toxic. A few examples have been chosen to represent
each of these mechanisms.
3.2.1. Liver Toxicity. The painkiller, APAP, can cause acute
hepatotoxicity in drug overdose.123 As previously discussed,
APAP is biotransformed during phase I metabolism into its
reactive metabolite NAPQI.124 Early studies identiﬁed that at
nontoxic doses of APAP, NAPQI can be detoxiﬁed by
conjugation with glutathione to be excreted from the body.125
The detoxiﬁcation mechanism is further evidenced by the
treatment with N-acetyl cysteine in overdosed patients to
decrease the eﬀects of hepatotoxicity126 Additionally, a
correlation was made between APAP-protein adducts and the
incidence of toxicity in mice. Using an immunohistochemical
approach, hepatic necrosis was found to correlate to a greater
presence of APAP adducts; it was deduced that toxicity was
caused by the binding of NAPQI to crucial proteins in the
liver.127 Collectively, these binding studies in APAP have
provided a framework to study other quinoneimines which
interact with nucleophilic residues on cellular macromole-
cules.128 Like APAP, the antimalarial drug amodiaquine, also
forms a quinonimine metabolite, which binds to crucial liver
proteins and causes liver necrosis.129 The RMs formed can have a
number of adverse eﬀects. For example, signiﬁcant lipid
peroxidation takes place in amodiaquine toxicity caused by free
radicals generated from the original RMs.130 However, RM-
modiﬁed proteins also have their own functional role in toxicity,
for example, amodiaquine adducts can activate an immune
response.131 A recent study in PD-1 (programmed cell death
protein 1) − /− mice demonstrated T-cell mediated reactions
upon treatment with amodiaquine.132 Another study has also
shown that even APAP has the potential to drive an adaptive
immune response.133 It is becoming more apparent that drug−
protein adducts have a functional role in immune activation.134
3.2.2. Mechanism Based Inhibition.MBI is a form of enzyme
inhibition which occurs when a RM binds to an enzyme. MBI can
be reversible, where RMs form a tight noncovalent bond through
coordination to the heme prosthetic group of the enzyme. In
contrast, irreversible inhibition involves covalent binding of RMs
with amino acid residues at the active site of the enzyme.
Covalent modiﬁcation of the enzyme can lead to antigen
formation and in some cases induce an autoimmune response.
The classical example ofMBI is tienilic acid which was withdrawn
from the market due to its hepatotoxic eﬀects. Tienilic acid was
released in the 1970s as a uricosuric diuretic drug. It is
bioactivated by CYP2C9; however, one of the reactive species
generated upon bioactivation also acts as a “suicide substrate”
and alkylates CYP2C9, thus inhibiting its function.120 One study
investigated tienilic acid with a closely related isomer to
demonstrate that the isomer can cause covalent binding to
various microsomal proteins but that only tienilic acid binds
CYP2C9 in a very speciﬁc manner.135 Antibodies against tienilic
acid have been detected which may be responsible for the
autoimmune responses.136,137 Lapatinib, a dual tyrosine kinase
inhibitor used for the treatment of breast cancer, is a more recent
example of a drug which acts as a mechanism based inhibitor of
CYP3A4. It is possible that lapatinib causes MBI of CYP3A4 via
covalent binding of a reactive quinoneimine metabolite to the
enzyme. Interestingly, Takakusa et al. demonstrated that MBI of
CYP3A4 by lapatinib was mainly due to the formation of quasi-
irreversible complex formed by a reactive nitroso intermediate
and the enzyme.138 Lapatinib is a particularly interesting example
to conclude this section because it is an MBI of CYP3A4, but it
has the ability to form a quinoneimine which could lead to direct
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toxicity. This toxicity has recently been associated with HLA
DRB1*07:01, which suggests the involvement of the immune
system.139,140 Though diﬀerent mechanisms are present within
drug toxicity, they seem to be linked as a chain of events. What is
becoming clearer is that the ﬁnal event in this chain is often the
activation of an immune response.
3.3. Immunological Activation. Immune responses to
drug−protein adducts manifest as both immediate IgE mediated
reactions and delayed type T-cell mediated reactions which are
clinically distinct (Figure 10). Various clinical outcomes may
occur with immediate reactions targeting the skin to cause rashes
and maculopapular exanthema and delayed reactions causing
more severe symptoms such as Stevens Johnson’s syndrome and
toxic epidermal necrolysis.141 In addition, the delayed nature of
idiosyncratic drug induced liver injury may also be attributed to
an underlying immunological mechanism.142
3.3.1. Immediate Hypersensitivity Reactions. Immediate
reactions are caused by the recognition of a drug or drug−protein
adducts by IgE antibodies. The formation of antigen speciﬁc IgE
is a B-cell mediated T-cell interaction. Upon initial exposure, a
drug modiﬁed peptide is presented to T-cells and B-cells. T-cells
provide stimulatory signals to B-cells which release antigen
speciﬁc IgE. The cross-linking of IgE initiates the release of
inﬂammatory mediators such as histamine, prostaglandins, and
cytokines. These inﬂammatory mediators establish a milieu of
cell stress resulting in the clinical eventualities described.141
Drug speciﬁc antibodies have been detected for a number of
drugs including penicillins, cephalosporins, and sulfamethox-
azole.143−145 Studies on immediate hypersensitivity to amox-
icillin have demonstrated the presence of highly speciﬁc IgE
antibodies which can recognize amoxicillin but not the
structurally similar compound benzylpenicillin.146 A number of
similar studies have taken place with other penicillins, which
corroborate the importance of the penicillin side chain in
determining the speciﬁcity of these reactions.143 While the
clinical manifestations of immediate and delayed type reactions
(DTRs) diﬀer, the mechanistic presentation of a drug modiﬁed
peptide to a T-cell is a shared molecular initiating event.
Therefore, drug−protein adducts play a central role in the
mechanism of drug induced hypersensitivity, making the study of
these adducts a focal point for research in this ﬁeld.
3.3.2. Mechanism of Delayed Type Hypersensitivity. Many
models for DTRs were ﬁrst studied by Landsteiner and Jacobs
when investigating the role of simple chemical compounds in the
sensitization of guinea pigs in allergic contact dermatitis.147
DTRs generally involve T-cell mediated adaptive immune
responses. However, additional danger signals mediated by the
innate immune system are essential for this to take place.148
Figure 10. Hapten model of drug hypersensitivity. Haptens are small molecules which can bind to proteins to become antigenic. These adducts are
recognized by the body’s immune system as foreign and are therefore taken up by antigen presenting cells. The conjugated protein is processed, and
peptide fragments are presented upon MHC. Self-peptides will not activate the immune system. It is understood that drug modiﬁed peptides presented
on MHC are responsible for activating T-cells in order to provoke an immune response. These T-cells can help to activate B-cells to release adduct
speciﬁc IgE, or they can become drug speciﬁc eﬀector T-cells to initiate an adaptive immune response. Antigen recognition alone (signal one) is not
enough to drive an immune event; an environment of cell stress and danger signaling (signal two) which can initiate the required costimulatory pathways
may be required to trigger an immune response.
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Drug−protein adducts play an important role in both innate and
adaptive immunity, and these interactions have been studied
extensively.149
3.3.3. Role of the Innate Immune System in Drug
Hypersensitivity. The innate immune system bridges the
deleterious eﬀects of direct RMs toxicity to the initiation of an
immune response. Direct toxicity causes cell death, which
initiates danger signaling. The release of damage associated
molecular patterns (DAMPs) can activate pattern recognition
receptors such as toll-like receptors (TLRs) and nucleotide-
binding oligomerization domain-like receptors (NLRs), leading
to upregulation of pro-inﬂammatory cytokine and chemokine
production.150 HMGB1, which is one such DAMP, has shown to
activate TLR2, −4, and −9 and is recognized as an early
biomarker for drug induced liver injury.150 NALP3 is an NLR
which forms an inﬂammasome upon activation. Inﬂammasomes
activate caspases which cleave pro-inﬂammatory cytokines to
their active form.151 Upon cell death in APAP induced liver
injury, free DNA released can activate TLR9 and interact with the
NALP3 inﬂammasome to contribute to hepatotoxicity.152 While
the pathways described are all downstream eﬀects of direct
toxicity, it is only in an environment of “danger signaling” in
which the maturation of dendritic cells (DCs) can occur. The
maturation of DCs is one of the key factors required to initiate an
adaptive immune response.
A number of studies have investigated the eﬀects of protein
modiﬁcation on the innate immune system, mainly pertaining to
contact allergens. Metal ions are common contact allergens; in
particular, nickel ions (Ni2+) have been shown to interact
covalently with histidine residues on TLR4. Ni2+ activates human
TLR4 but not mouse TLR4 via covalent binding of Ni2+ to
histidine residues that caused the dimerization of TLR4.153
Additionally, electrophiles such as DNCB and NAPQI can
activate nrf2 through covalent binding to cysteine residues within
the Keap1 protein.154,155 A better understanding of covalent
binding in innate immunity may provide therapeutic targets to
reduce the severity of drug hypersensitivity reactions.
3.3.4. Role of Adaptive Immunity in Drug Hypersensitivity.
Although multiple models of drug hypersensitivity exist, which
include a number of theories surrounding noncovalent
interactions between drugs and immune receptors, the hapten
mechanism requires a drug to covalently modify a protein for
antigen recognition. In order to prime naiv̈e T-cells, DCs
matured under the inﬂuence of danger signals are thought to
engulf a drug−protein adduct and present a drug modiﬁed
peptide to a naiv̈e T-cell resulting in drug-speciﬁcity. This forms
the basis for a T-cell mediated, adaptive immune response and
this interaction has been widely investigated.
β-Lactam antibiotics covalently bind to lysine residues on the
surface of proteins.5 Hans Ulrich Weltzein studied the
application of the hapten model in relation to β-lactam
hypersensitivity extensively. It has been shown that a portion
of the immunogenic epitope can be recognized by the T-cell.156
Synthetic peptides were used to explore the role of drug location
on a peptide sequence and their ability to induce an immune
response. This in vitro study demonstrated that penicillin-
modiﬁed peptides were responsible for an immune response in
humans.157 Another study altered the basic structure of penicillin
to remove the thiazolidine ring and the side chain deriving two
molecules: cefaclor and 6-aminopenicillinic acid.When tested for
immunogenicity neither molecule exhibited a response in
comparison to the unaltered drugs.158 This illustrated that the
precise structures of epitopes are important for T cell
recognition; hence, it is essential to characterize the exact nature
of antigen presented to T cells. SMX has been used as a model
drug for a number of early studies to support the hapten
hypothesis. Multiple mechanisms including both a covalent and
noncovalent interaction have been shown to activate immune
responses.92 As we have discussed, SMX can form a number of
reactive metabolites including SMX-NHOH and SMX-NO.
Using ﬂow cytometry, one study successfully stained these
metabolites being presented on the surface of neutrophils.159
Additionally, an increase of SMX-NO adducts have been
demonstrated under conditions of danger signaling.160 SMX
has also been shown to have a genetic link with the HLA DQ
gene family; this has been conﬁrmed by the presence of HLADQ
restricted CD4+ lymphocytes.161
Flucloxacillin induced liver injury has been shown to be
associated with HLA B*57:01.162 A ﬂucloxacillin adduct may be
responsible for activating a T-cell mediated response in the liver.
This has been conﬁrmed by the presence of drug speciﬁc T-cells
in patients.163 Mainly CD8+ T-cells expressing liver homing
receptors CCR4 and CCR9 were observed suggesting that these
T-cells could have the cytotoxic potential to destroy liver cells.
Flucloxacillin-speciﬁc T-cells were restricted by HLA B*57:01
and required antigen processing to trigger a T-cell response.
Antigen processing is determined using a pulsing assay. Here,
antigen presenting cells are incubated with a drug for a short
period of time before the drug is washed out. T-cell assays are
performed to speciﬁcally investigate the uptake of a drug antigen
and its presentation on a T-cell thus testing the hapten model.
Another study compared patient and volunteer clones to
illustrate that patients’ clones responded to ﬂucloxacillin protein
adducts, requiring antigen processing, whereas volunteer clones
could be stimulated by the drug directly without antigen
processing.164 Flucloxacillin-speciﬁc T cells generated in vitro
from healthy volunteers carrying HLA B*57:01 were shown to
be cytotoxic in the presence of liver cell lines transfected with
HLA B*57:01.165 Although these studies address the functional
aspects of T-cells and their recognition of the ﬂucloxacillin
molecule, the exact antigens responsible for activating drug-
speciﬁc T-cells still has not been identiﬁed. Some animal models
have identiﬁed ﬂucloxacillin protein adducts in the liver,122 but
no study has yet taken ﬂucloxacillin protein adducts generated in
vitro and shown a T-cell response.
On the contrary, studies in piperacillin have shown some
success in relating drug−protein adducts to their immunological
roles. Piperacillin hypersensitivity is common in patients with
cystic ﬁbrosis. A number of diﬀerent piperacillin albumin adducts
have been identiﬁed in patient plasma. These modiﬁcations have
been replicated and characterized in cell culture medium.
Piperacillin speciﬁc T-cell cones are also activated upon pulsing
Epstein−Barr virus transformed B cells (EBVs) with piperacillin.
Most importantly, synthetic piperacillin albumin conjugates have
been shown to activate piperacillin speciﬁc T-cells in vitro. To the
best of our knowledge, this is the only study which has
demonstrated the activation of a T-cell by a drug−protein
adduct.61 Interestingly, another study replicated these results
with the addition of ﬂucloxacillin albumin conjugates to
demonstrate that HSA bound to both ﬂucloxacillin and
piperacillin decreased T-cell proliferation against HSA bound
solely to piperacillin. Flucloxacillin-HSA conjugates did not
cross-react with piperacillin speciﬁc T-cells.19
NVP can cause skin and liver injury with a number of diﬀerent
genetic associations.166 It seems to be the case that the skin and
liver injury occur via diﬀerent pathways entirely. Sharma et al.
Chemical Research in Toxicology Review
DOI: 10.1021/acs.chemrestox.6b00147
Chem. Res. Toxicol. XXXX, XXX, XXX−XXX
P
successfully characterized the binding of NVP metabolites to
human and rat skin in vitro. A skin rash similar to that occurs in
humans was found to correlate to the covalent binding of NVP to
keratinocytes in a rat model.70 A major outcome of this study was
that the site of adduct formation occurred close to the reaction
location. However, an attempt to model NVP induced liver
injury in the samemanner showed the presence of extensiveNVP
adducts on hepatic tissues, but there was no evidence of liver
injury in the rats. They postulated that liver injury may be caused
due to the direct formation of a quinone methide RM.167
Therefore, diﬀerent clinical manifestations of a drug may be
mediated by entirely diﬀerent mechanisms. More recently, in a
mouse model, they have shown that NVP can produce signiﬁcant
liver injury when PD-1 was blocked, indicating immune tolerance
plays an important role in NVP induced liver injury.168
3.3.5. Advances in Understanding Immune-Mediated
Adverse Reactions. Although the idiosyncratic nature of these
reactions has been attributed to genetic variability among
patients,169 challenges still focus around identifying the chemical
nature of the antigenic determinants which are responsible for
these reactions. An understanding on how the ﬁeld of
immunology has progressed in recent years and advances in
the sensitivity of technology available to us can help deduce
whether the hapten model is still current within idiosyncratic
drug reactions.
Much progress has been made on understanding the
immunological mechanisms of adverse reactions since the initial
hapten hypothesis was postulated. In particular, recent genome
wide association studies have demonstrated that genetic
variability plays a key role in individual susceptibility. A number
of genetic associations have been found with drug induced
hypersensitivity reactions and many of these with HLA alleles.170
Although HLA alleles have shown to be linked with drug
hypersensitivity reactions, not every patient who is a carrier of
that allele will have an immune response. Co-stimulatory
pathways are involved in eliciting an immune response, and the
priming of naive T-cells to drugs has shown to be more eﬀective
when some of these pathways are blocked.171 It is evident that
genetic associations will be a key to understanding the individual
susceptibility; however, other factors including the chemical
nature and the level of antigen and the phenotype of the cell will
certainly have great impact on the severity of hypersensitivity.
4. DISCUSSION
Major advances in proteomics technology including two-
dimensional SDS−PAGE separation techniques combined with
MS and/or immunoblotting techniques have allowed for a more
precise identiﬁcation of protein targets and the exact location of
adducts.57 A large number of target proteins for drugs have been
identiﬁed, and a Web-accessible Target Protein Database is now
available for the storage of such information and to facilitate the
identiﬁcation of common protein modiﬁcation patterns of
diﬀerent drugs.172 In addition, quantitative analysis of drug−
protein adducts formed in vivo employing new proteomic
technologies is critical to unveiling the links between covalent
binding and organ toxicity. However, the progress in identifying
the functional roles of these drug−protein adducts has been
slowed by a number of diﬀerent challenges within the ﬁeld.
First, a large number of drugs associated with hypersensitivity
have been shown to form reactive metabolites that can modify
proteins both in vitro and in vivo, but the “reactive metabolite
theory of drug hypersensitivity” is still based primarily on a
“global association” between in vitro bioactivation and clinical
outcome. Because of a lack of data on absolute levels of in vivo
covalent binding that could lead to a toxic outcome, it is almost
impossible to determine whether the parent drug, stable
metabolite, or RMs are involved, and which protein targets are
critical for toxicity. Hapten density may also be an important
aspect in immunogenicity. Often, idiosyncratic drug reactions are
misidentiﬁed as being unrelated to the administered dose.
However, dosage can have a role in determining the clinical
outcome of a reaction. For this reason, the quantiﬁcation of
drug−protein adducts is essential. Additionally, there may be a
certain threshold for toxicity which can be identiﬁed retro-
spectively. The main issue is that at present, the technology to
investigate T-cell responses to short-lived chemically reactive
intermediates does not exist.173 Without this knowledge, it is
currently impossible to predict the potential for a given
compound that causes idiosyncratic toxicity via bioactivation.
Second, the nature of the antigenic determinants that trigger
an immunological response to drug−protein adducts remains to
be deﬁned. The most signiﬁcant study in drug hypersensitivity in
recent years has been unravelling the mechanism behind the
association between abacavir and HLA B*57:01.149,174 In this
study, peptides were eluted from drug treated EBV transformed
B cell lines, and the peptide repertoire was shown to change in
the presence of the drug. Early studies which investigated the
nature of drug modiﬁed peptides presented on MHC have yet to
be replicated, and there has been an absence of studies which
introduces a synthetic drug modiﬁed protein or peptide to
activate drug speciﬁc T-cell clones. As yet, this has only recently
been done with piperacillin modiﬁed albumin. The exact nature
of the drug−peptides which are presented have yet to be
elucidated. Another major challenge has been identifying the
mechanistic role of genetic associations. While ﬂucloxacillin has
shown HLA restricted responses in vitro, the preferential role of
these HLAs is still unknown for most drugs. Aside from abacavir,
the question has yet to be answered as to whether HLA’s have a
functional role in drug hypersensitivity reactions. Interestingly,
the pathway required for the release of IgE and also for an
adaptive immune response both require the formation of a drug−
protein adduct. Therefore, if the same signal 1 pathway manifests
as diﬀerent clinical phenotypes then there is a possibility that the
signal 2 pathway which is adduct independent may be the
determining factor in drug hypersensitivity reactions. This
further supports the importance of inter individual variation in
patients.
Accumulative evidence has shown that drug−protein con-
jugation has played a role in the pathogenesis of serious adverse
drug reactions, but whether it plays a predominant or an
accessory role will depend on multiple factors. It is now
appreciated that the frequency of adverse reactions is a sum of the
function of the chemistry of drug molecules, a function of the
biology of the cells, and a function of the genotype of patients.
Therefore, in vitro model systems to look at the interplay
between drug−protein conjugation factors, immunological
mechanisms, and genetic factors are to be developed in order
to deﬁne both chemical and biological variables that underpin
serious idiosyncratic adverse reactions. It must be stressed that
new in vitro model systems must be physiologically relevant to
ensure that their outcome reﬂects what is happening in humans.
Ultimately, the goal is to be able to investigate conjugate
formation in order to predict adverse drug reactions. Considering
the low incidence of these reactions, a prospective study would
have to be conducted on a massive scale.
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There is a growing list of drugs associated with idiosyncratic
drug reactions. With the resurgence of drugs designed inten-
tionally to covalently bind to their pharmacological targets, in
order to increase potency, there is a need to be ever vigilant to the
potential of drug to cause hypersensitivity during drug
development. There are a set of clear but challenging objectives
to be met for the progression of this ﬁeld. However, it is certain,
that this will be greatly assisted by the MS technology and
techniques available today.
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